News articles about Zafgen (NASDAQ:ZFGN) have trended somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Zafgen earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.6855247185605 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

ZFGN has been the subject of several analyst reports. ValuEngine cut shares of Zafgen from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 10th. Zacks Investment Research cut shares of Zafgen from a “buy” rating to a “hold” rating in a research note on Saturday, September 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $6.63.

Zafgen (NASDAQ ZFGN) opened at $3.76 on Thursday. Zafgen has a 52 week low of $3.11 and a 52 week high of $5.46.

Zafgen (NASDAQ:ZFGN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.12. equities research analysts forecast that Zafgen will post -2.02 earnings per share for the current fiscal year.

In other news, Director Frances K. Heller bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, October 13th. The stock was acquired at an average cost of $3.90 per share, with a total value of $39,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 21.20% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Zafgen (ZFGN) Earning Somewhat Positive Media Coverage, Accern Reports” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Insider Buying and Selling by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with's FREE daily email newsletter.